|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
10
|
|
pubmed:dateCreated |
2010-6-14
|
|
pubmed:abstractText |
The increase in type 2 diabetes mellitus is associated to cardiovascular morbidity and mortality. This review focuses on the benefits of the fixed-dose combination of perindopril and indapamide on cardiovascular and renal end points in the ADVANCE (Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation) trial.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
1744-7666
|
|
pubmed:author |
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
11
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1647-57
|
|
pubmed:dateRevised |
2011-8-25
|
|
pubmed:meshHeading |
pubmed-meshheading:20518617-Aged,
pubmed-meshheading:20518617-Angiotensin-Converting Enzyme Inhibitors,
pubmed-meshheading:20518617-Blood Pressure,
pubmed-meshheading:20518617-Diabetes Mellitus, Type 2,
pubmed-meshheading:20518617-Diuretics,
pubmed-meshheading:20518617-Drug Therapy, Combination,
pubmed-meshheading:20518617-Humans,
pubmed-meshheading:20518617-Hypertension,
pubmed-meshheading:20518617-Indapamide,
pubmed-meshheading:20518617-Middle Aged,
pubmed-meshheading:20518617-Perindopril
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Management of high blood pressure in type 2 diabetes: perindopril/indapamide fixed-dose combination and the ADVANCE trial [corrected].
|
|
pubmed:affiliation |
Department of Internal Medicine, University of Pisa, Via Roma 67, 56126 Pisa, Italy. l.ghiadoni@med.unipi.it
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial
|
